Studies

Showing:
All Disease States
Showing:
All Disease States

Studies Currently Underway

Studies Underway

QED Study: Surefire vs. Endhole for DEB-TACE - Quantifying Hepatic Artery Embolization to Improve Outcomes

This is a multi-center randomized controlled study comparing tumor response and medical outcomes for HCC (hepatocellular carcinoma or primary liver cancer) patients who undergo DEB-TACE with Surefire Infusion System vs. standard microcatheter.

Target Enrollment: 140
Status: Enrolling, Seeking New Sites

Learn More

Studies Underway

Surefire Precision Registry

Retrospective analysis of all Surefire Precision DEB-TACE cases in HCC patients. The study will look at overall response rate at 6 month.

Target Enrollment: 150
Status: Enrolling, Seeking New Sites

Learn More

Studies Underway

CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases

This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery using the Surefire Infusion System for patients with CEA-expressing liver metastases.

Target Enrollment: 5
Status: Enrolling

Learn More

Studies Underway

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

Randomized pilot study examining the use of the Surefire Infusion System to improve tumor perfusion. The study aims to determine if a Surefire Infusion System can improve tumor response to liver-directed intra-arterial chemotherapy compared to a traditional microcatheter.

Target Enrollment: 10
Status: Enrolling

Learn More

Studies Underway

Surefire Catheter versus Standard Endhole Microcatheter in Yttrium-90

This is a randomized controlled study comparing Surefire vs. standard microcatheter for delivery of glass microspheres in radioembolization procedures for HCC (hepatocellular carcinoma or primary liver cancer).

Target Enrollment: 20
Status: Enrolling

Learn More